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Abstract 
Background – Fatigue is a common manifestation of sarcoidosis, often persisting without evidence of 
disease activity. First-line therapies for sarcoidosis have limited effect on fatigue. This review aimed 
to assess the treatment options targeting sarcoidosis-associated fatigue. 
Search Methods – Medline and Web of Science were searched in November 2015; the bibliographies 
of these papers, and relevant review papers, were also searched. Studies were included if they 
reported on the efficacy of interventions (both pharmacological and non-pharmacological) on 
fatigue scores in sarcoidosis patients. 
Results – Eight studies were identified that fulfilled the inclusion criteria. These studies evaluated six 
different interventions (infliximab, adalimumab, ARA 290, methylphenidate, armodafinil and 
exercise programmes). Evidence to support a treatment effect of anti-TNF-alpha therapies 
(adalimumab and infliximab) and neurostimulants (methylphenidate and armodafinil), but within 
five of the studies the risk of bias was high within most domains and the remaining three studies 
included only small numbers of participants and were short in duration.  
Conclusions – Trial evidence for treating fatigue as a manifestation of sarcoidosis is limited and 
requires further investigation. Anti-TNF-alpha therapies may be beneficial in patients with organ-
threatening disease. Neurostimulants have some trial evidence supporting improvements in fatigue 
but further investigation is needed before they can be recommended. 
Registry number - CRD42015030079 
Abstract word count – 199 words 
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Introduction 
Fatigue is a common problem in patients with sarcoidosis. Its prevalence varies between studies, 
from 50%(1) to over 80% of patients(2), with a significant adverse impact on quality of life(3). The 
aetiology is poorly understood and likely to be multifactorial, encompassing active inflammation, 
cytokine release, depression, sleep disturbance and/or small-fibre neuropathy(4). Furthermore, 
systemic treatments used to treat sarcoidosis can themselves cause fatigue, including corticosteroids 
(5, 6). Management of this symptom can be challenging for physicians. Chronic fatigue in stable 
sarcoidosis patients was described as long ago as 1993, with management suggested to include 
“unremitting sympathy”(7); despite being identified as a feature of sarcoidosis for so long it remains 
a poorly understood and often forgotten problem. 
Identifying and treating any underlying and reversible causes of fatigue should be the first priority 
for any physician faced with a sarcoidosis patient with significant fatigue, which can include including 
sleep disordered breathing(8, 9) and periodic limb-movement syndromes(9). Once these have been 
excluded, strategies to improve fatigue should be considered. The evidence available for treatments 
of fatigue in sarcoidosis patients is limited. Few trials have specifically investigated treating fatigue, 
although measurement of fatigue is recommended as an outcome measure for trials involving 
sarcoidosis patients by the World Association of Sarcoidosis and Other Granulomatous Diseases 
(WASOG)(10).  
Various potential management strategies for sarcoidosis-fatigue have been suggested previously, 
including both pharmacological and non-pharmacological interventions. Tumour necrosis factor 
(TNF)-alpha is released by alveolar macrophages and is involved in the initial pathogenesis of 
sarcoidosis(11), as well as influencing prognosis(12). Anti TNF-alpha therapies have been 
investigated as a treatment for refractory sarcoidosis; amongst these trials, measurements of fatigue 
pre- and post-treatment have been taken. ARA 290(13), a novel peptide modelled on erythropoietin 
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that has anti-inflammatory and tissue protective activities, has also been investigated for its 
potential effects on symptoms of small-fibre neuropathy, including cognitive failure and fatigue(14).  
The use of neurostimulants has shown promise in treating other causes of fatigue. Methylphenidate, 
and it’s d-isomer dexmethylphenidate, act by inhibiting dopamine and noradrenaline transporters, 
elevating dopamine and noradrenaline levels within the brain(15). Methylphenidate is known for its 
use in attention-deficit hyperactivity disorder (ADHD)(16), but has been trialled for fatigue in other 
situations (including chemotherapy(17), post-radiotherapy(18), HIV(19), and Parkinson’s disease(20)) 
with some benefit. Modafinil and its enantiomer armodafinil are neurostimulants that are used for 
promoting wakefulness in narcolepsy. They have a complex profile of neurochemical effects which 
are different to those of amphetamines(21). 
Finally, physical activity programmes, including pulmonary rehabilitation in chronic obstructive 
pulmonary disease (COPD) patients, have been shown to have wide reaching benefits, including 
improving dyspnoea scores, health-related quality of life, anxiety and depression(22). The use of 
pulmonary rehabilitation in patients with interstitial lung diseases is recommended by guidelines(23, 
24), with evidence of benefit in this patient group similar to that seen in COPD patients(25). Recent 
trials investigating the use of such programmes in sarcoidosis patients and their impact on fatigue. 
The objective of this systematic review was to examine the evidence for treatments or management 
strategies of fatigue in sarcoidosis patients who are experiencing significant fatigue, as well as 
evaluating the quality of the evidence that presently exists, and to present the results of a 
qualitative analysis of the available data.  
Methods 
Publication Search 
This systematic review was registered with PROSPERO (registration number CRD42015030079) and 
was performed in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-
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Analysis (PRISMA) statement(26). The protocol can be accessed on the PROSPERO database using 
the registration number. The electronic databases Medline (using PubMed) and Web of Science 
were searched using the following search strategy: “sarcoid” OR “sarcoidosis” OR sarcoidosis [MeSH 
Terms] OR Sarcoid* (truncation) AND “fatigue” OR “chronic fatigue” OR “chronic fatigue syndrome” 
OR fatigue [MeSH Terms] OR fatigue syndrome, chronic [MeSH Terms] AND “treatment” OR 
“management” OR “clinical trial”. 
Bibliographies of appropriate papers, including review articles, was undertaken to identify relevant 
additional sources. The search included all trials published to the end of November 2015. The title 
and abstract of all papers identified were reviewed for relevance, with irrelevant studies and reports 
excluded. Remaining papers were reviewed in full. 
 
Selection Criteria 
Papers that were considered suitable for inclusion were any studies that evaluated the effect of an 
intervention or management strategy (pharmacological or non-pharmacological) on fatigue in 
sarcoidosis patients. All trial designs (case series, case-control, cross-over and parallel-arm 
randomised controlled trials) were included in the qualitative synthesis with the exception of single 
case reports, and so trials where no comparator group or comparator intervention were included. 
This ensured the broadest collection of evidence. The studies must have (1) evaluated sarcoidosis 
patients exclusively, or if the trial included other diseases then the sarcoidosis cohort had to 
evaluate sarcoidosis separately in the results, (2) evaluated the efficacy of the intervention on an 
assessment/measurement score of fatigue, (3) reported quantitative results for reduction in fatigue 
score between pre- and post-intervention results and (4) be presented in full-text form and in 
English. 
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Data Collection 
Data extraction was performed independently by the two authors (CA and AMW) using a checklist of 
data to extract. In addition, the Cochrane Collaboration’s tool for assessing risk of bias was also used 
to assess the methodological quality of each trial and identify possible sources of bias at a study 
level. The following data was collected: Main author’s last name, year of publication, study design, 
number of participants, severity of sarcoidosis in participants by chest X-ray staging (if given), 
intervention (including dose), duration of intervention, measurement score of fatigue used, change 
in fatigue outcome, number of participants reaching minimum clinically important difference on 
outcome score (if given), number of participants completing the intervention and adverse events 
reported within the trial. The summary measure of interest was mean improvement of fatigue score 
however a meta-analysis of data was not possible due to the heterogeneity of interventions and 
study designs included. Therefore a narrative review of the data is presented.  
 
 
Results 
Search results and characteristics of eligible trials 
The search strategy identified 150 records through Medline and 126 records through Web of 
Science. Two further papers of interest was identified through bibliography searches. Titles and 
abstracts were reviewed for relevance, with studies excluded if they did not include patients with 
sarcoidosis, were evaluating a potential intervention, or were review articles or case reports. A short 
list of 29 studies was identified, of which eight met the criteria for inclusion. The flow diagram 
(PRISMA 2009) of screening articles is shown in figure 1. Only three randomised controlled trials 
(either parallel arm or cross-over) were identified, the remaining articles consisted of two case-
control studies, three case series and one retrospective case review. Three papers evaluated formal 
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physical activity programs, two evaluated systemic treatment with tumour necrosis factor alpha 
(TNF-alpha) inhibitors, two evaluated symptom-targeted therapy with neurostimulants 
(dexmethylphenidate and armodafinil), and one trial looked at a novel molecule aimed at treating 
small-fibre neuropathy. All but one of the trials used the ‘Fatigue Assessment Scale’ (FAS), a ten-
point questionnaire with a maximum score of 50 points. This scale has been validated in sarcoidosis 
patients(27), has a well-defined cut-off score for fatigue of >21 points(27), and known minimal 
clinically important differences (MCID) of four points or 10% reduction(28). A total of 185 patients 
were included across all the trials. The details of the included studies are shown in table 1 (study 
information, safety and efficacy) and table 2 (risks of bias within studies). In addition, three papers 
that did not meet the inclusion criteria but provided useful information are discussed. 
 
Systemic therapy: anti-TNF-alpha treatment and anti-inflammatories 
Three trials evaluated interventions which have systemic or disease-modifying effects. Two 
investigated anti-TNF-alpha drugs (adalimumab(29) and infliximab(30)) and one investigated ARA 
290(13) Only one trial, investigating ARA 290(13), was a blinded, randomised-controlled trial; neither 
of the studies investigating anti-TNF-alpha therapies were of a randomised design.  
Erckens and colleagues(29) followed 26 sarcoidosis patients with refractory uveitis who had been 
commenced on Adalimumab (40mg subcutaneously once weekly) over a 12 months treatment 
period. All patients had previously received prednisolone and methotrexate. Fatigue was measured 
using the FAS, with 21 patients (80.7%) having a baseline FAS score >21 points. After the 12 month 
treatment period, there was a mean reduction in FAS score of 2.2 points and an improvement in FAS 
score in 14 of the 21 patients with a baseline FAS score >21 points; although it is not stated what 
constituted an improvement in the FAS and whether these patients met the MCID for the FAS score. 
The risk of bias is high with this trial design, as there is no comparator group to determine if this is a 
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placebo-effect or natural progression of the disease, however, there is a suggestion that fatigue is 
improved by anti-TNF-alpha therapy.  
In another study from the Netherlands, Van Rijswijk and colleagues(30) retrospectively reviewed 48 
sarcoidosis cases who required treatment with Infliximab (5mg/kg intravenously at 0, 2, 6, 10, 14 
and 18 weeks). All patients had previously received immunosuppression; 30 had received 
prednisolone and methotrexate, 12 received prednisolone only and 1 received methotrexate only. 
Data involving quality of life measures, including fatigue scores (within the ‘Checklist of Individual 
Strength’ questionnaire), had been collected pre-treatment in the most recent 27 cases. The fatigue 
score improved by a mean of 5.3 points from a baseline of 49.4 points (p=0.003), although it is not 
clear if this is a clinically important improvement. Furthermore, as this was a retrospective review, 
and without a comparator or placebo group, it is not possible to definitively attribute the change in 
fatigue scores to the intervention and does not conclude the benefits of TNF-inhibition in treating 
fatigue. 
Heij and colleagues(13) undertook a small double-blind, randomised controlled trial investigating the 
safety and efficacy of ARA 290 for symptoms of small fibre neuropathy in sarcoidosis patients. Only 
12 patients were included in the active treatment arm. Of these patients, four were receiving 
steroids and 1 received a systemic anti-inflammatory drug. Participants were excluded if they 
received an anti-TNF drug within six months of the trial. Fatigue was measured using the FAS score, 
though this was a secondary outcome. The baseline groups were imbalanced with regards to fatigue 
(mean FAS 37.9 in the ARA 290 group, 33.6 in the placebo group), but despite the higher levels of 
fatigue in the treatment arm at baseline there was an identical reduction in FAS scores over the four 
week trial period in both arms. There was no evidence that ARA 290 improved fatigue scores, but 
the trial was not powered for this outcome and was very short. It did show improvement in its 
primary outcome (the small fibre neuropathy screening list) as well as being well tolerated; if a 
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larger and longer trial investigating the drug were to be performed, measuring change in fatigue 
would be important to ensure that a treatment effect was not missed in this trial.  
 
Neuro-stimulants 
Two randomised-controlled trials, both using a cross-over design, investigated the use of 
neurostimulants for treating fatigue in sarcoidosis. One trial investigated the use of armodafinil(31) 
and one trial investigated dexmethylphenidate(32). In each trial the change in fatigue was the 
primary outcome being measured. 
Lower and colleagues(32) treated ten patients with sarcoidosis-related fatigue with 
dexmethylphenidate and assessed its response by measuring fatigue using the FAS score. 
Participants received up to 10mg twice daily of dexmethylphenidate or matched placebo and were 
investigated weekly for eight weeks per arm (treatment and placebo). All patients were receiving at 
least one systemic agent for their sarcoidosis. Treatment effect in the intervention arm was seen 
after five weeks of therapy, with a mean reduction of five points in the FAS score after eight weeks 
of treatment. The number of patients meeting the MCID was not reported. The drug was well 
tolerated, with no withdrawals. The small scale of the trial means that the results should be 
interpreted with caution, but suggests clinical benefit. 
In a cross-over trial by Lower and colleagues(31), fifteen patients with stable sarcoidosis received up 
to 250mg of armodafinil daily, all of whom underwent polysomnography and multiple sleep latency 
testing pre- and post-intervention. All participants had received systemic treatment for sarcoidosis 
(prednisolone, methotrexate, leflunomide, hydroxychloroquine, azathioprine or anti-TNF therapy) 
and nine were receiving continuous positive airway pressure therapy. There was a mean reduction 
of 4.5 points in the FAS score (the primary outcome) and nine patients (64%) exhibited a reduction 
of four points or more. Participants receiving armodafinil did have a prolonged sleep onset latency 
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compared with placebo which was statistically significant, although it is not clear if this was a 
clinically significant difference as no participants discontinued the medication due to insomnia. The 
paper did not report randomisation or allocation procedures, although it was double-blind and 
appeared an appropriate design for the study’s aims. The small number of patients and short period 
of the trial suggest that further evidence is needed to confirm the efficacy of armodafinil in this 
setting. 
 
Non-pharmacological treatment strategies 
Three recent papers have investigated the effect of structured physical training programmes on 
fatigue in sarcoidosis. Marcellis and colleagues(33) undertook an observational case-series study of 
twenty-four sarcoidosis patients in the Netherlands suffering with fatigue and/or impaired exercise 
tolerance. The intervention consisted of both upper- and lower-extremity peripheral muscle 
resistance training, with progressively increasing resistance through the training period, and 
endurance training, consisting of either treadmill or walking or cycling on an ergometer. Eighteen 
patients completed the entire training regime, with six not completing the programme. A statistically 
significant improvement was observed in FAS scores at the completion of the intervention: mean 
baseline and post-exercise FAS scores of 29.7 and 27.0 points respectively. Of the eighteen 
participants who completed the exercise programme, six patients (33.3%) had a reduction of four 
points in their FAS score; when using the alternative MCID of a 10% reduction, nine patients (50%) 
met this criteria. This study had no comparator group, it did not state how many patients were 
approached or screened for inclusion, and patients entering the trial and completing the exercise 
programme are likely to have been motivated to undertake such an intervention. Although the 
results from this study suggest that the intervention is beneficial for sarcoidosis-associated fatigue, it 
is unlikely to be beneficial in all patients. 
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Strookappe and colleagues(34) investigated physical activity programmes in a similar cohort of 
Dutch sarcoidosis sufferers in a retrospective observational study. From an initial cohort of 147 
sarcoidosis patients who had undergone physical performance assessment, 49 patients undertook a 
12-week supervised exercise programme. This was similar to that described by Marcellis and 
colleagues, with the peripheral muscles strengthening individualized for each patient. Twenty-one 
(42.9%) of the group were receiving steroids. A comparison was made with 41 sarcoidosis patients 
who had chosen not to undertake the programme but undertook identical physical assessments. 
Following re-assessment at the end of the 12-week period there was a statistically significant within-
group improvement in FAS scores in those who received physical therapy (29.8 pre, 25.6 post, 
p=0.009) whereas the comparator group had a non-significant reduction (pre 30.3, post 28.6, 
p=0.408). In the exercise programme group, 74.4% of patients had an improvement in their FAS 
score of four points or more, although 48.5% of the comparator group showed the same reduction 
despite not receiving any intervention. The within-group results suggest that physical training may 
be beneficial for fatigue, though the results should be interpreted with caution. As with the other 
trials investigating exercise programmes on fatigue, participants within the trial would have self-
selected as a group keen to undertake the intervention. Even given this source of bias, patients who 
chose not to receive the intervention reported a clinically significant improvement in their fatigue. 
Finally, although the authors state that blinding was not possible in this trial, it would be possible to 
blind assessors to patient groups when assessing physical and psychological parameters pre- and 
post-intervention; whether this occurred was not stated in the paper. 
Another study from Strookappe and colleagues(35) investigated the physical training in patients with 
end-stage sarcoidosis-related pulmonary fibrosis, alongside a cohort with idiopathic pulmonary 
fibrosis (IPF). Twelve patients with stage IV sarcoidosis participated in a 12-week exercise 
programme, similar to those described in the previous trials(33, 34). Patients were recruited from 
the same centre and during the same period as those included in another study by the same 
authors(34), though it is not specified whether these patients were also included in the results from 
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the earlier study. Despite this, the study was included as it reported the results of a sub-group of 
patients with end-stage pulmonary sarcoidosis, which were not reported separately in the other 
paper. FAS score was measured pre- and post-intervention. Baseline mean FAS score was 25.1 in the 
sarcoidosis group, with only six patients (50%) having clinically significant fatigue. Following the 
programme, four of the six patients reported improved fatigue, although the paper does not state 
whether participants that improved met the MCID for the FAS score. This study did not have a non-
intervention group, and only a small number of participants with fatigue at baseline were included. 
The same source of biases existed ass described with the other two studies investigating this 
intervention, making it difficult to be confident of the effect of physical training programmes for 
sarcoidosis patients suffering fatigue. 
 
Excluded Studies of Interest 
Two studies investigating anti-TNF-alpha therapy in large cohorts were not included in the 
systematic review; the first had no measurement of pre-treatment fatigue scores(14) and the second 
failed to describe a quantitative change in fatigue(36). One article describing methylphenidate use 
for sarcoidosis-associated fatigue was excluded because it was not a full article and did not describe 
a baseline fatigue score. Furthermore, one cross-sectional study has suggested that the anti-malarial 
hydroxychloroquine may have benefits on fatigue. 
One study investigating cognitive failure and sarcoidosis-associated fatigue in 343 patients was 
excluded as baseline assessment of fatigue occurred after patients had already been established on 
treatment(14). The study was a six-month cross-sectional assessment of patients who had already 
received various therapies, including TNF-inhibition in 42 patients. The results showed an 
improvement in FAS scores in the anti-TNF alpha therapy group over six months (baseline FAS 
32.8+/-7.31, six month change -4.90+/-5.57) when compared with patients on no treatment 
(baseline FAS 28.6+/-7.94, six month change 0.44+/-5.13), or on corticosteroids with or without 
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antimetabolite (methotrexate) therapy (baseline FAS 28.2+/-7.81, six month change +1.19+/-4.87). 
The patients in the anti-TNF-alpha therapy group had higher fatigue scores on their initial 
questionnaires compared with the other groups, and after six months there was no difference in 
fatigue scores between patients receiving other forms of therapy. However, without baseline 
characteristics in each group before commencing treatment it is not possible to directly compare the 
results of the groups, or establish the effect of treatment on fatigue scores. 
A further study investigating TNF-inhibitor treatment in sarcoidosis patients (adalimumab or 
infliximab) recorded pre-treatment fatigue levels in 111 patients was excluded because no numerical 
data for change in fatigue measure (FAS) were included(36). All patients had received prednisolone 
and methotrexate before receiving TNF blockade, and had evidence of ongoing disease activity 
despite treatment. Of the 111 patients included, 100 (90.1%) reported a FAS score >21 (mean 
baseline FAS 33.0) and 59 reported severe fatigue (FAS score >34). After 12 months of therapy 60 
patients who were fatigued at baseline had improvement in their fatigue score; unfortunately the 
definition of improvement and the scale of change in the FAS score required to be classified as a 
responder are not stated, therefore it is not possible to evaluate whether the intervention was 
clinically effective from these results. 
Methylphenidate was used in a series of five patients with severe sarcoidosis-associated fatigue that 
was described in a letter from Wagner and colleagues(37). Five patients received 10mg twice daily of 
methylphenidate. There was no formal measure of fatigue severity at baseline, but the paper 
describes a statistically significant reduction on the “Symptoms of Fatigue” scale after one month. 
There were positive reports from four of the five patients, with two reporting that they felt as if their 
lives were “back to normal”. The five patients continued on methylphenidate long-term; at two-
years, all five of the patients remained on methylphenidate and reported continuing improvement in 
fatigue, although no formal fatigue scoring was performed. The authors concluded that further 
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studies in larger groups of patients are required, though at the time of writing only the two small 
cross-over studies of armodafinil and dexmethylphenidate have been undertaken. 
Although no papers directly investigated the use of chloroquine or hydroxychloroquine for fatigue, a 
possible effect of the drug on fatigue scores was noted in a cross-sectional study comparing two 
cohorts of sarcoidosis patients(2). This paper was not included in this systematic review as it did not 
report change in fatigue scores pre- and post-treatment, but the authors noted that patients 
receiving hydroxychloroquine (n=22) had lower fatigue scores than patients on other agents in the 
absence of any other differences in disease activity or severity. The lack of pre- and post-treatment 
fatigue scores, as well as the small number of patients receiving the agent, mean that conclusions 
about the effectiveness of hydroxychloroquine for treating fatigue cannot be directly drawn from 
these results. 
 
Discussion 
The evidence base for treating fatigue in sarcoidosis remains weak. Only eight trials were identified, 
all of which have been presented here. Of these studies, all were either small or were of poor quality 
study design which led to the possibility of inherent biases affecting the results. This makes it 
difficult to draw strong conclusions about the benefits of each therapy. 
In patients with clinically significant fatigue with evidence of disease activity despite use of first line 
immunosuppressants, anti-TNF-alpha therapy may be indicated. In the absence of active, organ-
threatening disease the risks and potential side-effects of these drugs make them difficult to 
recommend for treating fatigue alone.  
Physical exercise programmes appear to lead to improvements in fatigue scores, but in the one trial 
that had a comparison group(34) almost half of the controls demonstrated clinically significant 
improvements in fatigue without any intervention. The patients who did enrol on the exercise 
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programmes were likely to have been motivated to undertake this and therefore most likely to 
benefit. Nevertheless, improvements were seen in physical measures beyond fatigue and so in 
patients with physical limitation and fatigue who express an interest in undertaking physical therapy 
a structured exercise programme may provide benefits. 
The management of fatigue in patients with quiescent disease is often a clinical challenge, especially 
given the potential side effects of disease-modifying medications. Neurostimulants such as modafinil 
or methylphenidate may be appropriate in these cases. The two trials investigating these 
interventions were well designed, but only included a small number of patients. Long-term use of 
these medications has been safe in other conditions (ADHD) but the trials investigating their use in 
sarcoidosis have been very short. Further evidence to investigate the longer-term safety and efficacy 
of these medications is required.  
Chloroquine and hydroxychloroquine are considered effective for treating cutaneous 
sarcoidosis(38). Its use in patients with sarcoidosis-associated fatigue who require corticosteroid 
therapy has been suggested in a previous review(39). The possible effectiveness of treating fatigue 
with these agents is interesting, but evidence from trials investigating pre- and post-intervention 
fatigue scores is needed before stronger recommendation can be made for its use.  
Future research considerations 
The main limitation of the evidence base for managing fatigue is the lack of trials of sufficient sample 
size or duration to make firm recommendations for managing patients with fatigue in clinical 
practice. Much of the data available are from observational studies or studies of less than 30 
patients. Any future trials investigating therapies for treating sarcoidosis should include fatigue as an 
outcome measure given the frequency and significance of fatigue in sarcoidosis cohorts. 
In patients with quiescent disease, where fatigue is the primary symptom driving treatment 
decisions, more randomised placebo controlled clinical trials are required. The need to eliminate any 
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placebo effect is important; in one of the trials included in this review (13) almost identical changes 
in fatigue from baseline were seen in both intervention and placebo arms. Designing these trials 
appropriately to inform clinical decision making is therefore the primary concern. The randomised 
trials that have already been performed have been very short, either four- or eight-weeks duration. 
Clinical use of agents such as neurostimulants would likely be over many months and future trials 
should therefore assess change in fatigue scores over a much longer period of time than previously 
seen, at least six months.  
There are limitations to this review. The review included only English language papers, although no 
papers in other languages were found in the search strategy. Although efforts were made to contact 
authors regarding missing data or unclear elements of trial design there remains gaps in the data 
presented here. Furthermore, the existing data is limited; the studies included involved only a small 
number of participants or followed a methodology that would include intrinsic bias.  
 
Conclusions 
The available data for treating sarcoidosis-associated fatigue is limited. Anti TNF-alpha therapies 
appear to improve fatigue but all data comes from observational trials without placebo arms. The 
neurostimulants dexmethylphenidate and armodafinil both appeared to improve fatigue scores 
compared with placebo but the trials were very small and short. Given the frequency that fatigue 
occurs in sarcoidosis, and the importance of this symptom for patients, larger and longer trials are 
necessary to help inform management decisions. The increasing awareness of fatigue as a 
problematic manifestation of sarcoidosis will hopefully ensure that any future trials investigating 
interventions for sarcoidosis will include measures of fatigue. 
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Table 1 – Overview of trials in sarcoidosis patients including change in fatigue as an outcome measure 
Author and Year Lower et al. 
2007 (32) 
Erckens et al. 
2011 (29) 
Heij et al. 
2012 (13) 
Van Rijswijk et al. 
2013 (30) 
Lower et al. 
2013 (31) 
Strookappe et al. 
2015 (35) 
Marcellis et al. 
2015 (33) 
Strookappe et al. 
2015 (34) 
Study Design Cross-over RCT Case series RCT Retrospective case 
review 
Cross-over RCT Case series Case series Retrospective, 
Observational 
Intervention Dex-
methylphenidate 
Adalimumab ARA 290 Infliximab Armodafinil Physical activity 
programme 
Physical activity 
programme 
Physical activity 
programme 
Dose Up to 10mg twice 
daily 
40mg S/C weekly 2mg IV weekly 5mg/kg IV at 
0,2,6,10,14 and 18 
weeks 
Up to 250mg twice 
daily 
12-week physical 
activity programme  
13-week physical 
activity programme 
12-week physical 
activity programme  
Comparator Placebo None Placebo None Placebo None None 41 patients who 
chose not to 
participate in 
programme 
Duration 8 weeks per arm 12 months 4 weeks 18 weeks 8 weeks per arm 12 weeks 13 weeks 12 weeks 
No. participants 10 26 22 (10 placebo) 27‡ 15 12 24 49 
% Male  20% 36.6% 50% 60% 33.3% 91.7% 75% 57.1% 
Age (mean ± SD) 52 (range 39-74) 51 ± 15 48.1 ± 2.7 48.9 ± 10.1 54 (range 35-62) 53.2 ± 11.7 49.4 ± 10.5 47.6 ± 11.3 
Disease stage 
(0/I/II/III/IV) 
Not stated 16/4/4/2/0 Not stated 5/7/14/5/14 3/5/2/2/3 0/0/0/0/12 0-I = 29.2% 
II-III = 66.6% 
IV = 4.2% 
4/11/22/0/4 
Measurement of 
fatigue 
FAS and FACIT-F FAS FAS ‘Fatigue severity’ 
within ‘Checklist 
Individual Strength’ 
FAS and FACIT-F FAS FAS FAS 
INTERVENTION: 
Pre- and Post- 
fatigue scores  
(mean ± S.D. 
unless stated) 
FAS (range): 
Pre: 32.5 (9-44) 
Post: 27.5 (23-43) 
FACIT-F (range): 
Pre: 19.5 (13-48) 
Post: 29.5 (5-50) 
Pre: 31.1 ± 11.1 
Post: 28.9 ± 10.0 
Pre: 37.9 ± 2.6 
Post: 33.3 ± 2.8 
Pre: 49.4 ± 9.2 
Change: -5.3 ± 8.5 
FAS (range): 
Pre: 37 (14-43) 
Change: -4.5 (-20, 
5) 
FACIT-F (range): 
Pre: 23 (10-47) 
Change: +9(-12,26) 
Pre: 28.5 ± 5.4 
Post: 27.7 ± 5.7 
(6 of the 12 
patients had FAS 
>21 at baseline) 
Pre: 29.7 ± 7.7 
Post: 27.0 ± 7.3 (in 
18 patients 
completing course) 
Pre: 29.8 ± 8.1 
Post: 25.6 ± 7.5 
COMPARATOR: 
Pre- and Post- 
fatigue scores  
(mean ± S.D. 
unless stated) 
Average scores in 
placebo arm†: 
FAS: 33.6±4.43 
FACIT-F: 24.3± 5.41 
N/A Pre: 33.6 ± 2.3 
Post: 29.8 ± 3.3 
N/A FAS (range): 
Pre: 37 (14-43) 
Change: +3.5 (-
9,14) 
FACIT-F (range): 
Pre: 23 (10-47) 
Change: -5 (-17,11) 
N/A N/A Pre: 30.3 ± 9.0 
Post: 28.6 ± 9.0 
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†Group values at the end of the placebo phase not given, data only presented as average values across placebo phase. 
‡48 patients included in study but quality of life scores (including fatigue) only available in 27. 
FAS = Fatigue Assessment Scale; FACIT-F = Functional Assessment of Chronic Illness Therapy – Fatigue; MCID = Minimal Clinically Important Difference   
Statistical 
difference vs. 
comparator 
FAS: p=0.0295 
FACIT-F: p=0.0040 
(between groups) 
P < 0.01 
compared with 
baseline 
Non-significant 
between groups 
P=0.003 compared 
with baseline 
FAS: p=0.0295 
FACIT-F: p=0.0040 
(between groups) 
Non-significant 
compared with 
baseline 
P = 0.003 
compared with 
baseline 
Within group 
(intervention): 
p=0.009 
Within group 
(placebo): p=0.408 
Groups not directly 
compared 
Number of 
participants with 
clinically 
significant 
improvement 
Not stated Not clear; 
14/21 less 
fatigued but 
doesn’t state 
MCID used. 
Not stated  Not stated 64% treated with 
armodafinil 
improved FAS by 4 
points (MCID); only 
7% in placebo  
66% of patients 
with FAS >21 at 
baseline had 
improvement in 
FAS, not specified 
if MCID used 
6 (3%) improve FAS 
by 4 points (MCID); 
9 (50%) improved 
FAS by 10% 
74.4% of 
intervention group 
and 48.5% of 
comparator group 
reduced FAS by 4 
points (MCID). 
Drop outs/ Side 
Effects 
No withdrawals 
4 patients required 
lower afternoon 
dose 
No withdrawals. 
1 severe injection 
site reaction 
No drop outs 3 patients 
discontinued within 
6 infusions: 
1) Allergic reaction 
2) Progression of 
dyspnoea 
3) Hepatitis (due to 
methotrexate) 
1 withdrawal due 
to severe anxiety 
No withdrawals 6 patients 
withdrew; 
3 = problems other 
than sarcoid 
2 = health 
insurance 
problems 
1= No reason 
Not stated 
Evidence of 
treatment effect 
in fatigue 
Yes Yes No Yes Yes Unclear Yes Yes 
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Table 2 – Risks of bias within trials in sarcoidosis patients reporting fatigue as an outcome measure 
Author and 
Year 
Lower et al. 
2007 (32) 
Erckens et al. 
2011 (29) 
Heij et al. 
2012 (13) 
Van Rijswijk et al. 
2013 (30) 
Lower et al. 
2013 (31) 
Strookappe et al. 
2015 (35) 
Marcellis et al. 
2015 (33) 
Strookappe et al. 
2015 (34) 
Sequence 
Generation 
LOW RISK 
Random 
sequence 
computer-
generated 
HIGH RISK 
No randomisation 
(NOT RCT) 
LOW RISK 
Computer 
generated 
randomisation 
code 
HIGH RISK 
No randomisation 
(NOT RCT) 
UNCLEAR 
No statement on 
randomisation 
procedure 
HIGH RISK 
No randomisation 
(NOT RCT) 
HIGH RISK 
No randomisation 
(NOT RCT) 
HIGH RISK 
No randomisation 
(NOT RCT) 
Allocation 
Concealment 
LOW RISK 
Pharmacy-
controlled 
allocation 
HIGH RISK 
No concealment, 
all patients 
receive drug 
LOW RISK 
Pharmacy-
controlled 
allocation 
HIGH RISK 
No concealment, 
all patients 
received drug 
UNCLEAR 
No statement on 
allocation 
procedure 
HIGH RISK 
No concealment, 
all patients on 
programme 
HIGH RISK 
No concealment, 
all patients on 
programme 
HIGH RISK 
No concealment, 
all patients on 
programme 
Blinding of 
participants, 
personnel and 
outcome 
assessors 
LOW RISK 
Double-blind with 
low risk of 
breaking blinding 
HIGH RISK 
No blinding 
LOW RISK 
Only allocating 
pharmacist 
unblinded 
HIGH RISK 
No blinding 
LOW 
Double-blind with 
low risk of 
breaking blinding 
HIGH RISK 
No blinding 
HIGH RISK 
No blinding 
HIGH RISK 
No blinding, inc. 
assessors of 
physical function 
pre- and post. 
Incomplete 
outcome data 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
LOW RISK 
Missing data 
compensated for 
by taking forward 
last value 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
Selective 
outcome 
reporting 
LOW 
All outcomes 
reported 
UNCLEAR 
No protocol 
available 
UNCLEAR 
No protocol 
available 
UNCLEAR 
No protocol 
available 
LOW 
All outcomes 
reported 
UNCLEAR 
No protocol 
available 
UNCLEAR 
No protocol 
available 
UNCLEAR 
No protocol 
available 
Other sources 
of bias 
No other clear 
causes of bias 
identified; cross-
over ensures 
groups balanced, 
patients are own 
controls. 
Small sample. 
Study design 
(case series) limits 
conclusions – no 
comparator group 
to eliminate 
placebo effect. 
Baseline 
imbalance in FAS 
and health status 
score (SF36) 
between groups – 
significantly lower 
fatigue scores in 
placebo arm. 
Retrospective 
review – data 
collected pre- and 
post-intervention 
but high risk of 
bias from 
retrospective 
nature 
No other clear 
causes of bias 
identified; cross-
over ensures 
groups balanced, 
patients are own 
controls. 
Small sample. 
Not an RCT, also 
participants 
enrolling on 
programme 
would self-select 
as motivated 
people, 
?generalisable 
Not an RCT, also 
participants 
enrolling on 
programme 
would self-select 
as motivated 
people, 
?generalisable 
Patients choosing 
the intervention 
would be a self-
selecting cohort; 
controls not 
randomised but 
refused 
intervention 
Overall risk of 
bias 
LOW – Well 
designed cross-
over trial, though 
only small sample 
HIGH – Study 
design (case 
series) means no 
blinding, 
randomisation or 
comparator. 
LOW – Well 
designed RCT but 
not powered to 
look at change in 
fatigue. 
HIGH – Design 
(retrospective 
case series) has 
no blinding, 
randomisation or 
comparator. 
UNCLEAR – Issues 
with description 
of randomisation 
allocation and 
concealment 
mean study at risk 
of bias 
HIGH - Study 
design (case 
series) means no 
blinding, 
randomisation or 
comparator. 
HIGH - Study 
design (case 
series) means no 
blinding, 
randomisation or 
comparator. 
HIGH – Self-
selecting 
intervention 
group, high risk of 
bias given control 
group declined 
intervention 
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